A newer therapy that acts like a Trojan horse to attack bacteria should be reserved for patients with certain treatment-refractory lung infections, according to updated nontuberculous mycobacterial (NTM) pulmonary disease guidelines released by the IDSA, the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the European Society of Clinical Microbiology and Infectious Disease (ESCMID).